African American patients with newly diagnosed multiple myeloma were less likely than White patients to receive drugs that ...

Exploring T-Cell Engager Therapy for Multiple Myeloma - Moffitt Cancer Center / cancer, Cell Coast 2026, Ken Shain, Moffitt ...

New research reveals that resistant myeloma cells import putrescine through the transporter SLC45A4, activating HOXA1-driven ...

A protocolized maintenance de-escalation permitted daratumumab cessation after ≥2 years plus ≥12 months sustained MRD negativity, with most patients not restarting at data cutoff. Generalizability is ...

A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...

Phase 3 Findings Mark Progress in Relapsed or Refractory Multiple Myeloma Treatment - Bristol Myers Squibb / BMS, Bristol ...

A real-world study of fifty multiple myeloma patients found that high-dose melphalan with autologous stem cell ...

Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma. Chari is a professor of clinical ...

When can we answer the question, "Is the treatment working?"After a few courses of treatment for multiple myeloma have passed, many patients likely wonder, "Is this treatment actually working?"The ...

Bristol Myers Squibb (BMY) on Thursday announced that it succeeded in a Phase 3 trial for a combination regimen containing Zenbexus, a treatment already available in the U.S. under the FDA’s ...

Bristol Myers Squibb (NYSE:BMY) reported new Phase 3 EXCALIBER-RRMM data for its Zenbexus combination in relapsed or ...